بمبروليزوماب مع أو بدون صيانة ساكيتوزوماب تيروموتيكان (ساك-TMT؛ MK-2870) في سرطان الرئة غير صغير الخلايا الحرشفي النقيلي (NSCLC) [MK-2870-023]
This study is for people with advanced squamous non-small cell lung cancer. It explores whether adding a new medication called sacituzumab tirumotecan (sac-TMT) to an existing treatment plan can improve outcomes. Initially, everyone receives a combination of Pembrolizumab, Carboplatin, and either Paclitaxel or Nab-paclitaxel for a few months. After this, participants are split into two groups by chance: one group continues with Pembrolizumab alone, while the other group receives Pembrolizumab plus sac-TMT. The main goal is to see if taking sac-TMT alongside Pembrolizumab helps people live longer compared to taking Pembrolizumab alone. It's a 'Phase 3' study, which means it's a larger trial comparing a new approach to standard care.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This research study is looking for better ways to treat a specific type of lung cancer called metastatic squamous non-small cell lung cancer. 'Metastatic' means the cancer has spread to other parts of the body. The study aims to see if adding a new drug, called sacituzumab tirumotecan (sac-TMT), to a standard treatment plan can help people live longer.
The study begins with a starting treatment phase. For about 12 weeks, all participants will receive a combination of three medicines: Pembrolizumab, Carboplatin, and either Paclitaxel or Nab-paclitaxel. These are given by drip (IV infusion).
After these initial 12 weeks, if your cancer hasn't worsened, you'll be randomly assigned to one of two groups. One group will continue to receive Pembrolizumab on its own (the current standard approach). The other group will receive Pembrolizumab plus the new drug, sac-TMT. By comparing these two groups, researchers hope to find out if adding sac-TMT is more effective at controlling the cancer and improving overall survival.
النقاط الرئيسية
- The study tests a new drug, sac-TMT, for advanced squamous lung cancer.
- It combines existing treatments with the new drug.
- The main aim is to see if the new combination helps people live longer.
- Participation involves an initial treatment phase, followed by random assignment to one of two groups.
- Regular hospital visits, tests, and scans are part of the study.
- It's a Phase 3 study, meaning it compares a new approach against standard care.
من قد يكون مؤهلاً؟
This study is specifically for adults aged 18 or older who have been diagnosed with squamous non-small cell lung cancer that has spread (stage IV).
To be considered, your doctors must be able to measure your cancer, and you should generally feel well enough to take part, with a good quality of life expected for at least three months. You'll also need to provide a sample of your cancer tissue. The study has specific health requirements, for example, your organs like your kidneys and liver need to be working properly.
If you have conditions like HIV, Hepatitis B, or Hepatitis C, you might still be able to join if these conditions are well-managed with treatment. Also, any side effects from previous cancer treatments should have mostly improved before you start the study. For those continuing into the second part of the study, your cancer should not have grown during the initial treatment phase.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Do you have squamous non-small cell lung cancer that has spread?
- هل عمرك 18 سنة أو أكثر؟
- Are you generally well enough to take part, with a good outlook for at least 3 months?
- Are your organs, like your liver and kidneys, working properly?
- Have any side effects from previous cancer treatments mostly gone away?
- Are you willing to provide a sample of your cancer tissue?
ماذا يتضمن المشاركة؟
Taking part in this study involves a few stages. First, everyone will receive an initial treatment for about 12 weeks. This involves an IV drip of Pembrolizumab, Carboplatin, and either Paclitaxel or Nab-paclitaxel, given every three weeks. During this time, you will have regular clinic visits, blood tests, and scans to check on your health and how the treatment is working. You'll also need to provide a sample of your cancer tissue.
After these first 12 weeks, if your cancer hasn't progressed, you will then be randomly assigned to one of two treatment groups. One group will continue with Pembrolizumab alone, and the other will receive Pembrolizumab plus sac-TMT. Both drugs are given by IV drip. You’ll have ongoing visits, tests, and scans to monitor your health and the treatment's effect. The total duration of your participation will depend on how you respond to the treatment and for how long the treatment benefits you.
المخاطر والفوائد المحتملة
Locations (217)
- CARTI Cancer Center ( Site 0006)الرمز البريدي المؤكدليتل روك، الولايات المتحدة· التوظيف
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122)الرمز البريدي المؤكدبوربانك، الولايات المتحدة· التوظيف
- Sharp Memorial Hospital ( Site 9544)الرمز البريدي المؤكدسان دييغو، الولايات المتحدة· التوظيف
- Intermountain Health Cancer Center Lutheran Hospital ( Site 0119)الرمز البريدي المؤكدجولدن، الولايات المتحدة· التوظيف
- Intermountain Health St. Mary's Regional Hospital ( Site 0116)الرمز البريدي المؤكدGrand Junction, United States· التوظيف
- Washington Hospital Center ( Site 0037)الرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة· التوظيف
- Mid Florida Hematology and Oncology Center ( Site 0109)الرمز البريدي المؤكدمدينة أورانج، الولايات المتحدة· مكتمل
- Centricity Research Columbus Cancer Center ( Site 0111)الرمز البريدي المؤكدكولومبوس، الولايات المتحدة· مكتمل
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001)الرمز البريدي المؤكدماريتا، الولايات المتحدة· مكتمل
- Southeastern Regional Medical Center ( Site 0004)الرمز البريدي المؤكدNewnan, United States· مكتمل
- University of Chicago Medical Center ( Site 0145)الرمز البريدي المؤكدشيكاغو، الولايات المتحدة· التوظيف
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552)الرمز البريدي المؤكدYpsilanti, United States· التوظيف
أسئلة شائعة
ما نوع السرطان الذي تدرس هذه الدراسة؟
This study is for people with advanced squamous non-small cell lung cancer that has spread to other parts of the body.
ما هي الأهداف الرئيسية لهذه الدراسة؟
The main goal is to see if adding a new drug, sac-TMT, to a standard treatment helps people with this type of lung cancer live longer.
هل سأعرف أي علاج سأحصل عليه؟
After an initial treatment period, you will be randomly assigned to one of two groups. You will know if you are receiving Pembrolizumab alone or Pembrolizumab plus sac-TMT.
كم من الوقت سأكون في الدراسة؟
The length of your participation will depend on how well the treatment works for you and as long as you continue to benefit from it.
ماذا يحدث إذا أردت التوقف عن المشاركة؟
You can leave the study at any time, for any reason, without it affecting your future medical care.
كيفية معرفة المزيد
رقم مجاني
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.